留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

HLA基因多态性与药物性肝损伤的关系

王露媛 姜敏杰 高普均

王露媛, 姜敏杰, 高普均. HLA基因多态性与药物性肝损伤的关系[J]. 临床肝胆病杂志, 2021, 37(2): 475-479. DOI: 10.3969/j.issn.1001-5256.2021.02.048
引用本文: 王露媛, 姜敏杰, 高普均. HLA基因多态性与药物性肝损伤的关系[J]. 临床肝胆病杂志, 2021, 37(2): 475-479. DOI: 10.3969/j.issn.1001-5256.2021.02.048
WANG LY, JIANG MJ, GAO PJ. Association between human leukocyte antigen gene polymorphism and drug-induced liver injury [J]. J Clin Hepatol, 2021, 37(2): 475-479. DOI: 10.3969/j.issn.1001-5256.2021.02.048
Citation: WANG LY, JIANG MJ, GAO PJ. Association between human leukocyte antigen gene polymorphism and drug-induced liver injury [J]. J Clin Hepatol, 2021, 37(2): 475-479. DOI: 10.3969/j.issn.1001-5256.2021.02.048

HLA基因多态性与药物性肝损伤的关系

DOI: 10.3969/j.issn.1001-5256.2021.02.048
基金项目: 

“艾滋病和病毒性肝炎等重大传染病防治”国家科技重大专项 2017ZX10202202

“艾滋病和病毒性肝炎等重大传染病防治”国家科技重大专项 2018ZX10302206

“艾滋病和病毒性肝炎等重大传染病防治”国家科技重大专项 2018ZX10723203

国家重点研发计划“精准医学研究”专项 2017YFC0908103

吉林省自然科学基金 2018SCZWSZX-003

吉林省自然科学基金 JLSCZD2019-008

吉林大学高层次创新团队建设项目 2017TD-08

详细信息
    作者简介:

    王露媛(1993—),男,主要从事肝脏疾病的临床研究

    通讯作者:

    高普均,gpj0411@163.com

  • 作者贡献声明:王露媛、高普均负责拟定写作思路;王露媛、姜敏杰负责检索文献,资料分析,参与收集数据;王露媛负责撰写文章;高普均负责指导撰写文章并最后定稿。
  • 中图分类号: R575

Association between human leukocyte antigen gene polymorphism and drug-induced liver injury

  • 摘要: 药物性肝损伤是临床常见的药物不良反应之一,其临床诊治极为困难,且易发展成急性肝衰竭。相关药物基因组学研究已发现人类白细胞抗原(HLA)基因与药物性肝损伤之间有很强的遗传相关性。综述了药物性肝损伤的HLA基因多态性研究进展,以期揭示免疫因素在药物性肝损伤发生机制中的作用,发现相应基因生物标志物,提高临床用药的安全性。
  • 表  1  HLA基因多态性与常见DILI的相关性

    药物 HLA基因 人群 OR 参考文献
    阿莫西林-克拉维酸 DRB1*15:01 苏格兰 9.25 [12]
    阿莫西林-克拉维酸 DRB1*15:01-DQB1*06:02 欧洲 3.3 [7]
    阿莫西林-克拉维酸 A*02:01 欧洲 2.2 [7]
    氟氯西林 B*57:01 英国 80.6 [8]
    米诺环素 A*35:02 高加索 29.6 [6]
    甲氧苄啶-磺胺甲噁唑 B*14:01 欧翳美国人 9.2 [32]
    甲氧苄啶-磺胺甲噁唑 B*35:01 非翳美国人 - [32]
    希美加群 DRB1*07-DQA1*02 英国 4.4 [18]
    拉帕替尼 DRB1*07:01 高加索 6.9~14.1 [34-35]
    拉帕替尼 DRA1*02:01 高加索 9.0~14.1 [34-35]
    帕唑帕尼 B*57:01 全球 - [36]
    何首乌 B*35:01 中国 86.51) [43]
    何首乌 B*35:01 中国 143.92) [43]
    卡马西平 A*31:01 欧洲 7.3 [39]
    英夫利昔单抗 B*39:01 欧洲 43.6 [44]
    氟吡汀 DRB1*16:01-DQB1*05:02 德国 18.7 [38]
    注:1)治疗对照组;2)人群对照组。
    下载: 导出CSV
  • [1] Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769.(in Chinese) DOI: 10.3969/j.issn.1001-5256.2015.11.002

    中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002
    [2] KULLAK-UBLICK GA, ANDRADE RJ, MERZ M, et al. Drug-induced liver injury: Recent advances in diagnosis and risk assessment[J]. Gut, 2017, 66(6): 1154-1164. DOI: 10.1136/gutjnl-2016-313369
    [3] VEGA M, VERMA M, BESWICK D, et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: Preliminary findings from gastroenterologist-based surveillance in the population of the state of delaware[J]. Drug Saf, 2017, 40(9): 783-787. DOI: 10.1007/s40264-017-0547-9
    [4] SHEN T, LIU YX, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. DOI: 10.1053/j.gastro.2019.02.002
    [5] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261. DOI: 10.1016/j.jhep.2019.02.014
    [6] URBAN TJ, NICOLETTI P, CHALASANI N, et al. Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor[J]. J Hepatol, 2017, 67(1): 137-144. DOI: 10.1016/j.jhep.2017.03.010
    [7] LUCENA MI, MOLOKHIA M, SHEN Y, et al. Susceptibility to amoxicillin-clavulanate- induced liver injury is influenced by multiple HLA class I and Ⅱ alleles[J]. Gastroenterology, 2011, 141(1): 338-347. DOI: 10.1053/j.gastro.2011.04.001
    [8] DALY AK, DONALDSON PT, BHATNAGAR P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin[J]. Nat Genet, 2009, 41(7): 816-819. DOI: 10.1038/ng.379
    [9] AITHAL GP, GROVE JI. Genome-wide association studies in drug-induced liver injury: Step change in understanding the pathogenesis[J]. Semin Liver Dis, 2015, 35(4): 421-431. DOI: 10.1055/s-0035-1567829
    [10] URBAN TJ, DALY AK, AITHAL GP. Genetic basis of drug-induced liver injury: Present and future[J]. Semin Liver Dis, 2014, 34(2): 123-133. DOI: 10.1055/s-0034-1375954
    [11] FAN WL, SHIAO MS, HUI RC, et al. HLA association with drug-induced adverse reactions[J]. J Immunol Res, 2017, 2017: 3186328. http://www.ncbi.nlm.nih.gov/pubmed/29333460
    [12] GROVE JI, AITHAL GP. Human leukocyte antigen genetic risk factors of drug-induced liver toxicology[J]. Expert Opin Drug Metab Toxicol, 2015, 11(3): 395-409. DOI: 10.1517/17425255.2015.992414
    [13] USUI T, NAISBITT DJ. Human leukocyte antigen and idiosyncratic adverse drug reactions[J]. Drug Metab Pharmacokinet, 2017, 32(1): 21-30. DOI: 10.1016/j.dmpk.2016.11.003
    [14] CHIPINDA I, HETTICK JM, SIEGEL PD. Haptenation: Chemical reactivity and protein binding[J]. J Allergy (Cairo), 2011, 2011: 839682. http://www.ncbi.nlm.nih.gov/pubmed/21785613
    [15] YANG X, TU RF, YANG JH. Research advances in drug-induced liver injury[J]. J Clin Hepatol, 2020, 36(3): 509-513. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.03.006

    杨雪, 涂荣芳, 杨晋辉. 药物性肝损伤的研究进展[J]. 临床肝胆病杂志, 2020, 36(3): 509-513. DOI: 10.3969/j.issn.1001-5256.2020.03.006
    [16] BAI ZF, GAO Y, ZUO XB, et al. Progress in research on the pathogenesis of immune regulation and idiosyncratic drug-induced liver injury[J]. Acta Pharmaceutica Sinica, 2017, 52 (7): 1019-1026. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YXXB201707001.htm

    柏兆方, 高源, 左晓彬, 等. 免疫调控与特异质型药物性肝损伤发生机制研究进展[J]. 药学学报, 2017, 52(7): 1019-1026. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXB201707001.htm
    [17] WUILLEMIN N, ADAM J, FONTANA S, et al. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin[J]. J Immunol, 2013, 190(10): 4956-4964. DOI: 10.4049/jimmunol.1202949
    [18] KINDMARK A, JAWAID A, HARBRON CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis[J]. Pharmacogenomics J, 2008, 8(3): 186-195. DOI: 10.1038/sj.tpj.6500458
    [19] PIRMOHAMED M, OSTROV DA, PARK BK. New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity[J]. J Allergy Clin Immunol, 2015, 136(2): 236-244. DOI: 10.1016/j.jaci.2015.06.022
    [20] ILLING PT, MIFSUD NA, PURCELL AW. Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions[J]. Curr Opin Immunol, 2016, 42: 31-40. DOI: 10.1016/j.coi.2016.05.003
    [21] WATKINS S, PICHLER WJ. Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRVβ20-1, altering pHLA recognition[J]. PLoS One, 2013, 8(10): e76211. DOI: 10.1371/journal.pone.0076211
    [22] CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2014, 109(7): 950-966; quiz 967. DOI: 10.1038/ajg.2014.131
    [23] HAUTEKEETE ML, HORSMANS Y, VAN WAEYENBERGE C, et al. HLA association of amoxicillin-clavulanate--induced hepatitis[J]. Gastroenterology, 1999, 117(5): 1181-1186. DOI: 10.1016/S0016-5085(99)70404-X
    [24] DONALDSON PT, DALY AK, HENDERSON J, et al. Human leucocyte antigen class Ⅱ genotype in susceptibility and resistance to co-amoxiclav-induced liver injury[J]. J Hepatol, 2010, 53(6): 1049-1053. DOI: 10.1016/j.jhep.2010.05.033
    [25] STEPHENS C, LÓPEZ-NEVOT MÁ, RUIZ-CABELLO F, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity[J]. PLoS One, 2013, 8(7): e68111. DOI: 10.1371/journal.pone.0068111
    [26] MA Q, YANG W, WANG L, et al. Research advances in the association of drug-induced liver injury with polymorphisms in human leukocyte antigen[J]. Int Immunopharmacol, 2020, 81: 106037. DOI: 10.1016/j.intimp.2019.106037
    [27] WING K, BHASKARAN K, PEALING L, et al. Quantification of the risk of liver injury associated with flucloxacillin: A UK population-based cohort study[J]. J Antimicrob Chemother, 2017, 72(9): 2636-2646. DOI: 10.1093/jac/dkx183
    [28] WUILLEMIN N, TERRACCIANO L, BELTRAMINELLI H, et al. T cells infiltrate the liver and kill hepatocytes in HLA-B(*)57:01-associated floxacillin-induced liver injury[J]. Am J Pathol, 2014, 184(6): 1677-1682. DOI: 10.1016/j.ajpath.2014.02.018
    [29] MONSHI MM, FAULKNER L, GIBSON A, et al. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury[J]. Hepatology, 2013, 57(2): 727-739. DOI: 10.1002/hep.26077
    [30] NICOLETTI P, AITHAL GP, CHAMBERLAIN TC, et al. Drug-induced liver injury due to flucloxacillin: Relevance of multiple human leukocyte antigen alleles[J]. Clin Pharmacol Ther, 2019, 106(1): 245-253. DOI: 10.1002/cpt.1375
    [31] BJÖRNSSON E, TALWALKAR J, TREEPRASERTSUK S, et al. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis[J]. Hepatology, 2010, 51(6): 2040-2048. DOI: 10.1002/hep.23588
    [32] LI YJ, PHILLIPS E, DELLINGER A, et al. HLA-B*14: 01 and HLA-B*35: 01 are associated with trimethoprim-sulfamethoxazole induced liver injury[J]. Hepatology, 2020.[Epub ahead of print]
    [33] CHALASANI N, BONKOVSKY HL, FONTANA R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study[J]. Gastroenterology, 2015, 148(7): 1340-1352. DOI: 10.1053/j.gastro.2015.03.006
    [34] SCHAID DJ, SPRAGGS CF, MCDONNELL SK, et al. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury[J]. J Clin Oncol, 2014, 32(22): 2296-2303. DOI: 10.1200/JCO.2013.52.9867
    [35] SPRAGGS CF, BUDDE LR, BRILEY LP, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer[J]. J Clin Oncol, 2011, 29(6): 667-673. DOI: 10.1200/JCO.2010.31.3197
    [36] XU CF, JOHNSON T, WANG X, et al. HLA-B*57:01 confers susceptibility to pazopanib-associated liver injury in patients with cancer[J]. Clin Cancer Res, 2016, 22(6): 1371-1377. DOI: 10.1158/1078-0432.CCR-15-2044
    [37] XIANG Q, ZHANG Z, WU Y, et al. HLA polymorphisms and TKI-induced liver injury in patients with cancer: A Meta-analysis[J]. J Cancer, 2019, 10(10): 2161-2168. DOI: 10.7150/jca.26727
    [38] NICOLETTI P, WERK AN, SAWLE A, et al. HLA-DRB1*16:01-DQB1*05:02 is a novel genetic risk factor for flupirtine-induced liver injury[J]. Pharmacogenet Genomics, 2016, 26(5): 218-224. DOI: 10.1097/FPC.0000000000000209
    [39] NICOLETTI P, BARRETT S, MCEVOY L, et al. Shared genetic risk factors across carbamazepine-induced hypersensitivity reactions[J]. Clin Pharmacol Ther, 2019, 106(5): 1028-1036. DOI: 10.1002/cpt.1493
    [40] WANG XL, HUANG JJ, WANG B, et al. Correlation between HLA-B and drug induced liver injury caused by atypical antipsychotics[J]. J Pschiatry, 2016, 29(5): 346-349. (in Chinese) DOI: 10.3969/j.issn.2095-9346.2016.05.008

    王晓良, 黄晶晶, 王飚, 等. HLA基因多态性与非典型抗精神病药物性肝损伤关联性研究[J]. 精神医学杂志, 2016, 29(5): 346-349. DOI: 10.3969/j.issn.2095-9346.2016.05.008
    [41] WANG R, QI X, YOSHIDA EM, et al. Clinical characteristics and outcomes of traditional Chinese medicine-induced liver injury: A systematic review[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(4): 425-434. DOI: 10.1080/17474124.2018.1427581
    [42] LEI X, CHEN J, REN J, et al. Liver damage associated with polygonum multiflorum thunb.: A systematic review of case reports and case series[J]. Evid Based Complement Alternat Med, 2015, 2015: 459749. http://www.ncbi.nlm.nih.gov/pubmed/25648693
    [43] LI C, RAO T, CHEN X, et al. HLA-B*35:01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans[J]. Hepatology, 2019, 70(1): 346-357. http://www.ncbi.nlm.nih.gov/pubmed/30985007
    [44] BRUNO CD, FREMD B, CHURCH RJ, et al. HLA associations with infliximab-induced liver injury[J]. Pharmacogenomics J, 2020, 20(5): 681-686. DOI: 10.1038/s41397-020-0159-0
    [45] BJÖRNSSON ES, GUNNARSSON BI, GRÖNDAL G, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists[J]. Clin Gastroenterol Hepatol, 2015, 13(3): 602-608. DOI: 10.1016/j.cgh.2014.07.062
    [46] BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425. DOI: 10.1053/j.gastro.2013.02.006
  • 加载中
表(1)
计量
  • 文章访问数:  18
  • HTML全文浏览量:  1
  • PDF下载量:  9
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-08-08
  • 修回日期:  2020-10-19
  • 刊出日期:  2021-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回